Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates

Journal of Medical Primatology

Volumn 38, Issue 4, 2009, Pages 263-271

  Promadej Lanier, Nattawan ^a   Smith, James M ^a   Srinivasan, Priya ^a   McCoy, Clare F ^b   Butera, Sal ^a   Woolfson, A David ^b   Malcolm, R Karl ^b   Otten, Ron A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

HIV interventions; Macaques; Mucosal transmission; SHIV

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICROBICIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SILASTIC; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; COLPOSCOPY; COMPRESSION; COMPRESSION STRENGTH; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; INFLAMMATION; MATERIALS TESTING; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE RESEARCH; RHESUS MONKEY; SUSTAINED RELEASE FORMULATION; VAGINA RING; VAGINAL DISCOMFORT;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-HIV AGENTS; EQUIPMENT AND SUPPLIES; FEMALE; HIV; MACACA MULATTA; MACACA NEMESTRINA; MECHANICS;

MACACA; MACACA MULATTA; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS; SUIDAE;

EID: 67650445842     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2009.00354.x     Document Type: Article

References (44)

1. Ahrendt HJ, Nisand I, Bastianelli C, Gomez MA, Gemzell-Danielsson K, Urdl W, Karskov B, Oeyen L, Bitzer J, Page G, Milsom I: Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3mg of drospirenone. Contraception 2006; 74: 451-7.
2. Al-Azzawi F, Buckler HM: Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric 2003; 6: 118-27.
3. Al-Harthi L, Kovacs A, Coombs RW, Reichelderfer PS, Wright DJ, Cohen MH, Cohn J, Cu-Uvin S, Watts H, Lewis S, Beckner S, Landay A: A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. Aids 2001; 15: 1535-43.
4. Alfano M, Crotti A, Vicenzi E, Poli G: New players in cytokine control of HIV infection. Curr HIV/AIDS Rep 2008; 5: 27-32.
5. Barentsen R, van de Weijer PH, Schram JH: Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997; 71: 73-80.
6. Buckler H, Al-Azzawi F: The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. BJOG 2003; 110: 753-9.
7. Creinin MD, Meyn LA, Borgatta L, Barnhart K, Jensen J, Burke AE, Westhoff C, Gilliam M, Dutton C, Ballagh SA: Multicenter comparison of the contraceptive ring and patch: A randomized controlled trial. Obstet Gynecol 2008; 111: 267-77.
8. Duncan G: Medicated devices and methods patent. US Patent 3,545,439. 1970.
9. Dziuk PJ, Cook B: Passage of steroids through silicone rubber. Endocrinology 1966; 78: 208-11.
10. Elkind-Hirsch KE, Darensbourg C, Ogden B, Ogden LF, Hindelang P: Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception 2007; 76: 348-56.
11. Ellenberger D, Otten RA, Li B, Aidoo M, Rodriguez IV, Sariol CA, Martinez M, Monsour M, Wyatt L, Hudgens MG, Kraiselburd E, Moss B, Robinson H, Folks T, Butera S: HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology 2006; 352: 216-25.
12. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC: HIV vaccine research: The way forward. Science 2008; 321: 530-2.
13. Fichorova RN: Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune Defic Syndr 2004; 37 (Suppl. 3): S184-93.
14. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, Lipscomb J, Johnson JA, Delinsky D, Schinazi RF, Janssen R, Folks TM, Heneine W: Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5: E28.
15. Girard MP, Osmanov SK, Kieny MP: A review of vaccine research and development: The human immunodeficiency virus (HIV). Vaccine 2006; 24: 4062-81.
16. Gupta P, Ozel B, Stanczyk FZ, Felix JC, Mishell DR Jr: The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Menopause 2008; 15: 94-7.
17. Hardy E, Hebling EM, Sousa MH, Almeida AF, Amaral E: Delivery of microbicides to the vagina: Difficulties reported with the use of three devices, adherence to use and preferences. Contraception 2007; 76: 126-31.
18. Vickery BH: Disposable intravaginal contraceptive devices releasing 1-substituted imidazoles patent. US Patent 4,553,972. 1985.
19. Johnston MI, Fauci AS: An HIV vaccine -challenges and prospects. N Engl J Med 2008; 359: 888-90.
20. Kim CN, Adams DR, Bashirian S, Butera S, Folks TM, Otten RA: Repetitive exposures with simian/human immunodeficiency viruses: Strategy to study HIV pre-clinical interventions in non-human primates. J Med Primatol 2006; 35: 210-6.
21. Kirton KT, Roseman TJ, Forbes AD: Evaluation of progesterone-containing silicone vaginal devices in rhesus monkeys. Contraception 1973; 8: 561-8.
22. Kragt CL, Gala RR: Luteinizing hormone-releasing hormone, ovariectomy, and silastic vaginal rings in the Rhesus monkey. Fertil Steril 1977; 28: 856-62.
23. Malcolm K, Woolfson D: Blocking the heterosexual transmission of HIV: intravaginal rings for the controlled delivery of topical microbicides. Drug Del Syst Sci 2001; 1: 117-21.
24. Malcolm K, Woolfson D, Russell J, Andrews C: In vitro release of nonoxynol-9 from silicone matrix intravaginal rings. J Control Release 2003; 91: 355-64.
25. Malcolm RK: Vaginal rings for controlled-release drug delivery. In: Modified-Release Drug Delivery Technology. Rathbone, Roberts, Hadgraft & Lane (eds), 2nd edn. Taylor & Francis, Inc, New York, 2008, pp. 507-18.
26. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD: Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005; 56: 954-6.
27. McMichael AJ: HIV vaccines. Annu Rev Immunol 2006; 24: 227-55.
28. Mishell DR Jr, Lumkin ME: Contraceptive effect of varying doses of progestogen in Silastic vaginal rings. Fert Steril 1970; 21: 99-103.
29. Mishell DR Jr, Talas M, Parlow AF, Moyer DL: Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol 1970; 107: 100-7.
30. Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu SL, Johnson RP, Lifson J, Montefiori D, Moore J, Robert-Guroff M, Robinson H, Self S, Corey L: The use of nonhuman primate models in HIV vaccine development. PLoS Med 2008; 5: E173.
31. Otten RA, Adams DR, Kim CN, Jackson E, Pullium JK, Lee K, Grohskopf LA, Monsour M, Butera S, Folks TM: Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: Strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis 2005; 191: 164-73.
32. Padian NS, Buve A, Balkus J, Serwadda D, Cates W Jr: Biomedical interventions to prevent HIV infection: Evidence, challenges, and way forward. Lancet 2008; 372: 585-99.
33. Patton DL, Sweeney YC, Cummings PK, Meyn L, Rabe LK, Hillier SL: Safety and efficacy evaluations for vaginal and rectal use of BufferGel in the macaque model. Sex Transm Dis 2004; 31: 290-6.
34. Promadej-Lanier N, Srinivasan P, Curtis K, Adams DR, Kim C, Luo W, Jia H, Subbarao S, Otten RA, Butera S: Systemic and mucosal immunological responses during repeated mucosal SHIV(162P3) challenges prior to and following infection in pigtailed macaques. Virology 2008; 375: 492-503.
35. Roumen FJ, op ten Berg MM, Hoomans EH: The combined contraceptive vaginal ring (NuvaRing): First experience in daily clinical practice in The Netherlands. Eur J Contracept Reprod Health Care 2006; 11: 14-22.
36. Scorpio DG, Ruben DS, Liao Z, Hildreth JE, Fletcher CA: Cervicovaginal evaluation in macaques used as a model for topical microbicide safety studies. J Med Primatol 2008; 37 (Suppl. 1): 65-73.
37. Shively CA, Wood CE, Register TC, Willard SL, Lees CJ, Chen H, Sitruk-Ware RL, Tsong YY, Cline JM: Hormone therapy effects on social behavior and activity levels of surgically postmenopausal cynomolgus monkeys. Psychoneuroendocrinology 2007; 32: 981-90.
38. Smith DJ, Wakasiaka S, Hoang TD, Bwayo JJ, Del Rio C, Priddy FH: An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: Behaviors and attitudes that might influence uptake within a high-risk population. J Womens Health (Larchmt) 2008; 17: 1025-34.
39. Subbarao S, Ramos A, Kim C, Adams D, Monsour M, Butera S, Folks T, Otten RA: Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention. J Med Primatol 2007; 36: 238-43.
40. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359: 463-72.
41. Vree M: Lower hormone dosage with improved cycle control. Eur J Contracept Reprod Health Care 2002; 7 (Suppl. 2): 25-30; discussion 37-9.
42. Wood CE, Sitruk-Ware RL, Tsong YY, Register TC, Lees CJ, Cline JM: Effects of estradiol with oral or intravaginal progesterone on risk markers for breast cancer in a postmenopausal monkey model. Menopause 2007; 14: 639-47.
43. Woolfson A, Malcolm R, Morrow R, Toner C, McCullagh S: Potential use of vaginal rings for prevention of heterosexual transmission of HIV: A controlled-release strategy for HIV microbicides. Am J Drug Delivery 2006; 4: 7-20.
44. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD: Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006; 325: 82-9.